Novel method for diagnosis and therapy of bladder cancer by targeting urinary CD55/CD9 double-positive exosomes

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K09384
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56030:Urology-related
• Research Institution: St. Marianna University School of Medicine
• Principal Investigator: Kikuchi Eiji 聖マリアンナ医科大学, 医学部, 教授 (10286552)
• Co-Investigator(Kenkyū-buntansha): 吉岡 祐亮 (吉岡祐亮) 東京医科大学, 医学部, 講師(特任) (60721503) ; 薄場 渉 聖マリアンナ医科大学, 医学部, 助教 (90867649)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 膀胱癌 / エクソソーム / CD55 / ExoScreen / バイオマーカー

Outline of Final Research Achievements

The purpose of this study is to validate the usefulness of urinary CD55+9+exosome, which is upregulated in bladder cancer patients, as a diagnostic and prognostic marker for bladder cancer, and to elucidate the role of CD55+9+exosome in the tumor environment of bladder cancer patients. Quantification of urinary CD55+9+exosomes using the ExoScreen method proved to be a very useful diagnostic method for bladder cancer. Urinary CD55+9+exosome levels were associated with bladder cancer grade and invasion, suggesting that they may be prognostic markers for recurrence and stage progression. Cisplatin exposure was found to increase CD55+9+exosome secretion in bladder cancer cell lines. This indicates that CD55+9+exosome may also contribute to resistance to anticancer drugs.

Free Research Field

泌尿器科学

Academic Significance and Societal Importance of the Research Achievements

従来検討されてきた尿中の膀胱腫瘍マーカーは感度、特異度や尿中安定性に問題があるが、CD55+9+exosomeはそれらの問題をクリアできる可能性を持つ。さらに、今回尿中CD55+9+exosomeの定量は膀胱癌の診断法として有用であることが示され、即時に臨床応用が可能なExoScreen法を用いることで、新たな診断法開発の早期実現が期待できる。